ACAD•benzinga•
Acadia Pharmaceuticals And Saniona Announce Initial Results From ACP-711 (formerly SAN711) Phase 1 Study; ACP-711 Was Safe And Generally Well Tolerated Across All Dosing Cohorts. There Were No Serious Adverse Events, And All Participants Completed The Stu
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 3, 2025 by benzinga